Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB3205
- Development stage
- Phase 1
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
TQB3205 is an orally administered pan-KRAS inhibitor and targeted protein degrader (TPD) being developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of Sino Biopharmaceutical. As a national Category 1 innovative drug in China, it is designed to target multiple KRAS mutation subtypes, including G12V, G12D, and G13D, potentially addressing a broader patient population than existing G12C-specific inhibitors. TQB3205 is currently being evaluated in Phase I clinical trials for its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced malignant tumors, including those with pancreatic, colorectal, and lung cancers.
02
Targets
Beyond the preview
Go deeper on TQB3205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB3205.